Publications by authors named "A Alpuente"
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review.
Methods: Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy.
Background And Purpose: Patients presenting at the emergency room (ER) with headache often encounter a hostile atmosphere and experience delays in diagnosis and treatment. The aim of this study was to design a protocol for the ER with the goal of optimizing the care of patients with urgent headache to facilitate diagnosis and expedite treatment.
Methods: A narrative literature review was conducted via a MEDLINE search in October 2021.
Migraine-related stigma is a pervasive issue impacting nearly half of chronic migraine patients, with significant consequences for their quality of life, disability and mental health. Despite its profound effects, migraine stigma remains under-recognised in both clinical practice and research. This narrative review explores the three primary types of stigmas affecting migraine patients: public, structural and internalised.
View Article and Find Full Text PDFArticle Synopsis
- OnabotulinumtoxinA (BTX-A) has been recognized for its positive effects on chronic migraine since its initial link 25 years ago and received FDA approval for treatment in 2010.
- The treatment significantly enhances the quality of life for individuals suffering from chronic migraine by offering insights into its neuromodulatory effects and biological mechanisms.
- This Review discusses the breadth of clinical research, including trials and real-world evidence, while also exploring future research directions for BTX-A in migraine management.
Background: Real-world studies have shown the sustained therapeutic effect and favourable safety profile of OnabotulinumtoxinA (BoNTA) in the long term and up to 4 years of treatment in chronic migraine (CM). This study aims to assess the safety profile and efficacy of BoNTA in CM after 5 years of treatment in a real-life setting.
Methods: We performed a retrospective chart review of patients with CM in relation to BoNTA treatment for more than 5 years in 19 Spanish headache clinics.